AMGN vs GILD Stock Comparison: AI Score, Valuation, Performance and Upside
Amgen and Gilead Sciences are both established biotechnology companies managing legacy product competition while pursuing new growth areas, with Amgen defending against biosimilar competition while building an obesity drug pipeline, and Gilead Sciences defending its dominant HIV franchise while expanding into oncology.
Amgen offers exposure to an established, diversified biotechnology platform with obesity drug pipeline upside, while Gilead Sciences offers exposure to a dominant, durable HIV franchise with newer prevention therapies extending its growth. Consider whether you prefer Amgen's obesity pipeline optionality or Gilead's HIV franchise durability.
GILD holds the edge across 3 of 5 key metrics in this comparison. AMGN has delivered stronger 1-year price return (+55.67% vs +37.21%), though GILD has the better forward P/E setup (14.73x vs 15.46x for AMGN). On fundamentals, GILD is growing revenue faster (10.20%), while AMGN maintains the higher operating margin (35.55%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for GILD (+8.05%) than for AMGN (+2.83%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to an established biotechnology platform across oncology, inflammation, and bone health
- Believe the emerging obesity drug pipeline offers meaningful long-term growth potential
- Are comfortable with ongoing biosimilar competition pressuring legacy product revenue
- See value in a company with deep biologics manufacturing and development expertise
- Want exposure to a dominant, durable HIV treatment and prevention franchise
- Believe newer HIV prevention therapies extend the growth runway beyond legacy products
- Value diversification progress into oncology beyond the core HIV business
- Prefer a company with an established, high-margin core revenue base
| Metric | AMGN | GILD |
|---|---|---|
| AI scorei | 52.3 | 53.9 |
| AI ranki | #600 | #507 |
| Latest closei | $461.26 | $167.47 |
| 1M returni | +14.45% | +15.70% |
| 3M returni | +18.27% | +23.82% |
| 6M returni | +39.95% | +25.46% |
| 1Y returni | +55.67% | +37.21% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AMGN | GILD |
|---|---|---|
| 1Y ago | $15.55K (+55.5%) started 2025-11-04 | $13.62K (+36.2%) started 2025-11-04 |
| 5Y ago | $27.64K (+176.4%) started 2021-11-05 | $33.68K (+236.8%) started 2021-11-05 |
| 10Y ago | $58.09K (+480.9%) started 2016-11-07 | $44.86K (+348.6%) started 2016-11-07 |
Hypothetical — past performance does not guarantee future results.
| Metric | AMGN | GILD |
|---|---|---|
| Market capi | $204.01B | $180.64B |
| Trailing P/Ei | 23.42 | 17.74 |
| Forward P/Ei | 15.46 | 14.73 |
| Price/Salesi | 4.57 | 4.87 |
| EV/Revenuei | 6.49 | 6.63 |
| Analyst targeti | $388.03 | $157.41 |
| Target upsidei | +2.83% | +8.05% |
| Metric | AMGN | GILD |
|---|---|---|
| Revenue growthi | 9.50% | 10.20% |
| Earnings growthi | 64.90% | 54.80% |
| EPS growthi | +64.90% | +54.80% |
| FCF margini | +22.69% | +32.07% |
| Operating margini | 35.55% | 33.68% |
| Profit margini | 22.95% | -10.64% |
| ROIC proxyi | 91.47% | -20.68% |
| Return on equityi | 91.47% | -20.68% |
| Dividend yieldi | 2.64% | 2.20% |
| Payout ratioi | 60.87% | 43.46% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.43 | 0.34 |
| Debt/equityi | 490.28 | 223.47 |
| Current ratioi | 1.37 | 1.26 |
| Quick ratioi | 0.95 | 0.90 |
Over the past year, AMGN and GILD have moved moderately in the same direction (correlation of 0.53), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | AMGN | GILD |
|---|---|---|---|
| 1Y | Growthi | +55.46% | +36.15% |
| CAGRi | +55.56% | +36.21% | |
| Volatilityi | 29.73% | 27.10% | |
| Sharpe ratioi | 1.51 | 1.13 | |
| Sortino ratioi | 2.38 | 1.81 | |
| Max drawdowni | 16.57% | 22.03% | |
| Current drawdowni | 0.00% | 0.00% | |
| Avg drawdowni | 6.03% | 8.23% | |
| Ulcer Indexi | 7.71% | 10.34% | |
| Max daily dropi | 10.08% | 3.72% | |
| Max wkly dropi | 15.03% | 5.98% | |
| 5Y | Growthi | +143.32% | +190.37% |
| CAGRi | +19.48% | +23.78% | |
| Volatilityi | 24.93% | 24.96% | |
| Sharpe ratioi | 0.66 | 0.80 | |
| Sortino ratioi | 1.00 | 1.25 | |
| Max drawdowni | 24.86% | 26.59% | |
| Current drawdowni | 0.00% | 0.00% | |
| Avg drawdowni | 8.16% | 8.88% | |
| Ulcer Indexi | 10.34% | 10.93% | |
| Max daily dropi | 10.08% | 10.15% | |
| Max wkly dropi | 15.03% | 9.78% | |
| 10Y | Growthi | +330.92% | +210.20% |
| CAGRi | +15.74% | +12.00% | |
| Volatilityi | 25.14% | 25.67% | |
| Sharpe ratioi | 0.53 | 0.40 | |
| Sortino ratioi | 0.79 | 0.59 | |
| Max drawdowni | 24.86% | 30.47% | |
| Current drawdowni | 0.00% | 0.00% | |
| Avg drawdowni | 7.89% | 12.92% | |
| Ulcer Indexi | 9.77% | 14.94% | |
| Max daily dropi | 10.08% | 10.15% | |
| Max wkly dropi | 15.03% | 12.29% |
| Category | AMGN | GILD |
|---|---|---|
| Company | Amgen Inc. | Gilead Sciences, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | A global biotechnology company with an established portfolio spanning oncology, inflammation, and bone health treatments, alongside a growing obesity drug pipeline, working to manage biosimilar competition on legacy products. | A biopharmaceutical company with a leading HIV treatment and prevention franchise, alongside a growing oncology portfolio, focused on maintaining its dominant position in HIV therapeutics while diversifying revenue into new disease areas. |
| Investor focus | Growth of newer drugs including obesity pipeline candidates, biosimilar competition trends on legacy products, and dividend sustainability given the maturity of its established portfolio. | HIV franchise durability and growth from newer treatment and prevention therapies, oncology pipeline progress, and overall pipeline diversification beyond its core HIV business. |
- Established biotechnology platform with deep expertise across oncology, inflammation, and bone health treatment categories
- Emerging obesity drug pipeline provides exposure to one of the fastest-growing pharmaceutical categories
- Long operating history and manufacturing scale support efficient production and distribution of biologic therapies
- Dominant, long-standing position in HIV treatment and prevention provides a durable, high-margin core revenue base
- Newer HIV prevention therapies extend the franchise's growth runway beyond legacy treatment products
- Growing oncology portfolio provides diversification beyond its historically core HIV business
- Legacy biologic products face ongoing biosimilar competition that pressures revenue over time
- Obesity drug pipeline remains in earlier competitive stages relative to some established rivals in that category
- Biotechnology manufacturing and pipeline development require sustained, significant research and development investment
- Significant revenue concentration in its HIV franchise creates exposure if new treatment approaches or competitors emerge
- Oncology pipeline diversification efforts must succeed to meaningfully reduce dependence on the core HIV business
- Faces eventual patent expiration risk across its HIV product portfolio over the long term
Compare more than two at a time
This page is a fixed writeup on AMGN and GILD. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside AMGN and GILD, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.